Literature DB >> 1272639

Enzymatic diagnosis and carrier detection of aspartylglucosaminuria using blood samples.

P Aula, K Raivio, S Autio.   

Abstract

The activity of the glycoprotein degrading lysosomal hydrolase, 4-L-aspartylglycosylamine amido hydrolase (AAD Gase, EC.3.5.1.26), was measured in plasma, buffy coat leukocytes, and separated lymphocytes (Ficoll separation) from 16 patients with aspartylglucosaminuria (AGU), 29 obligate heterozygotes, and 30 control subjects. In lymphocytes the AGU patients had unmeasurable or minimal AAD Gase activity with a mean of 3.9 U. The obligate heterozygotes showed AAD Gase activities ranging from 5 to 69 U with a mean of 34.1 U. Enzyme activities in the control group ranged from 91 to 243 U with a mean of 127.9 U, and were clearly separated from the values of the heterozygotes. In leukocytes the AGU patients had unmeasurable enzyme activity and obligate heterozygotes had enzyme levels closely similar to those in the lymphocytes from the same individuals. The AAD Gase activity in the leukocytes of the control group displayed a much wider variation than in the lymphocytes, ranging from 22 to 132 U with a mean of 70.7 U. In plasma the AGU patients had undetectable AAD Gase activity. The mean enzyme level of obligate heterozygotes was 72.2 U and that of control individuals 107.2 U, but the overlap between the groups was extensive. The results indicate that homozygous deficiency of AAD Gase, i.e., aspartylglucosaminuria can be reliably diagnosed using plasma, leukocytes, or separated lymphocytes. For carrier detection only separated lymphocytes allow a satisfactory differentiation between heterozygous and normal individuals. A group of 31 siblings of verified AGU cases and 11 children of identified carriers, whose spouses had normal AAD Gase activity, were investigated using the lymphocyte assay. The observed and expected frequencies (on the basis of Mendelian probabilities) were closely similar, suggesting that the lymphocyte assay can be used reliably for carrier detection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1272639     DOI: 10.1203/00006450-197606000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Purification and some properties of 1-aspartamido-beta-N-acetylglucosamine amidohydrolase from human liver.

Authors:  B Dugal; J Stromme
Journal:  Biochem J       Date:  1977-09-01       Impact factor: 3.857

3.  Aspartylglycosaminuria in Northern Norway in eight patients: clinical heterogeneity and variations with the diet.

Authors:  O Borud; J H Strömme; S O Lie; K H Torp
Journal:  J Inherit Metab Dis       Date:  1978       Impact factor: 4.982

4.  Metabolism of collagen in aspartylglycosaminuria: decreased synthesis by cultured fibroblasts.

Authors:  K Näntö-Salonen; R Penttinen
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

Review 5.  Aspartylglycosaminuria: an inborn error of glycoprotein catabolism.

Authors:  C P Maury
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

6.  Variation of urinary excretion of aspartylglucosamine and associated clinical findings in aspartyglucosaminuria.

Authors:  P Aula; K O Raivio; P Maury
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

7.  Linkage of aspartylglucosaminuria (AGU) to marker loci on the long arm of chromosome 4.

Authors:  K Grön; P Aula; L Peltonen
Journal:  Hum Genet       Date:  1990-07       Impact factor: 4.132

8.  Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease.

Authors:  E Ikonen; M Baumann; K Grön; A C Syvänen; N Enomaa; R Halila; P Aula; L Peltonen
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.